The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
115296298 11529629 8 F 20150915 20160721 20150921 20160727 EXP CA-ROCHE-1636706 ROCHE 55.48 YR F Y 0.00000 20160727 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
115296298 11529629 1 PS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 300 MG SOLUTION FOR INJECTION
115296298 11529629 2 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 3 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 4 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 5 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 6 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 7 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 8 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 9 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060,S0061D,S0062,S0066B,S0002F 103976 SOLUTION FOR INJECTION
115296298 11529629 10 C ADVAIR HFA FLUTICASONE PROPIONATESALMETEROL XINAFOATE 1 Unknown U 0
115296298 11529629 11 C SINGULAIR MONTELUKAST SODIUM 1 Unknown U 0
115296298 11529629 12 C VENTOLIN ALBUTEROL SULFATE 1 Unknown U 0
115296298 11529629 13 C PREDNISONE. PREDNISONE 1 Oral U 0 40 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
115296298 11529629 1 Asthma
115296298 11529629 10 Product used for unknown indication
115296298 11529629 11 Product used for unknown indication
115296298 11529629 12 Product used for unknown indication
115296298 11529629 13 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
115296298 11529629 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
115296298 11529629 Blood pressure increased
115296298 11529629 Body temperature increased
115296298 11529629 Heart rate increased
115296298 11529629 Hypertension

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
115296298 11529629 1 20150915 0
115296298 11529629 2 20160107 0
115296298 11529629 3 20160204 0
115296298 11529629 4 20160303 0
115296298 11529629 5 20160331 0
115296298 11529629 6 20160427 0
115296298 11529629 7 20160526 0
115296298 11529629 8 20160623 0
115296298 11529629 9 20160721 0